Technical Data
E3440-13
Epstein Barr Virus, Latent Membrane Protein (EBV LMP, Human Herpes virus 4, HHV4)
Description:
This pool of four monoclonal antibodies detects the latent membrane protein (LMP-1) derived from the BNLF1 gene of Epstein-Barr virus (EBV). This antibody cocktail will help detect EBV infected cells in normal and uncharacterized tissues.

Applications:
Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: 1:100-1:200 for 1hr at RT
Optimal dilutions to be determined by the researcher.

Positive Control:
Lymph node, Hodgkin’s disease (about 50% of cases are likely to be positive). Cytoplasmic staining pattern may be observed in Reed Sternberg cells.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG1CS1, CS2, CS3, CS4Supernatant
SizeStorageShippingSourceHost
1ml-20°CBlue IceMouse
Concentration:
Not determined
Immunogen:
Fusion protein including sequences of the EBV encoded latent membrane protein (LMP-1) and bacterial beta-galactosidase.
Purity:
Supernatant
Form
Supplied as a lyophilized powder in 15mM sodium azide. Reconstitute with 1ml dH2O.
Specificity:
Recognizes Epstein Barr Virus.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1.Murray P G, Young L S, Rowe M, et al.. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin’s disease. Journal of Pathology. 166:1-5 (1992). 2.Herbst H, Dallenbach F, Hummel M, et al.. Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphoma. Blood. 78:1-10 (1991). 3.Jarrett R F, Gallagher A, Jones D B, et al.. Detection of Epstein-Barr virus genomes in Hodgkin’s disease: Relation to age. Journal of Clinical Pathology. 44:844-848 (1991). 4.Pallesen G, Hamilton-Dutoit S J, Rowe M, et al.. Expression of Epstein-Barr (EBV) latent gene products in tumor cells of Hodgkin’s disease. Lancet. 337:320-322 (1991). 5.Haribuchi Y, Yamanaka N, Katura A, et al.. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal medline granuloma. Lancet. 335:128-130 (1990). 6.Young L, Alfieri C, Hennesy K, et al.. Expression of Epstein-Barr virus transformation-associated genes in tissue of patients with EBV lymphoprolifera- tive disease. New England Journal of Medicine. 321:1080-1085 (1989).
7.Fahraeus R, Li-Fu H, Ernberg I, et al.. Expression of the Epstein-Barr virus genome in nasopharyngeal carcinoma. International Journal of Cancer. 42:329-338 (1988). 8.Rowe M, Evans H S, Young L S, et al.. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. Journal of General Virology. 68:1575-1586 (1987).